RxDoctor Payments Data

Edward Kenshock, OD

Optometrist · Fayetteville, NCNPI 1417980913

Payments from drug & device makers

$617in general payments, 2019–2025

Across 25 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$257
  • AbbVie$236
  • Alcon$90
  • Bausch & Lomb Americas Inc.$19
  • Eyevance Pharmaceuticals LLC$14

What the payments were for

  • Food & beverage$617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$617 in reported general payments places this provider in the 35th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$256,780
Medicare patients
1,081
Services billed
3,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine85$115,420
LumiganBimatoprost160$87,847
VyzultaLatanoprostene Bunod55$24,417
XiidraLifitegrast21$24,264
Alphagan PBrimonidine Tartrate37$18,475
CombiganBrimonidine Tartrate/Timolol43$14,306
SimbrinzaBrinzolamide/Brimonidine Tart35$9,959
Latanoprost628$8,783
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol45$7,330
Travoprost47$6,525
Brimonidine Tartrate77$6,508
ZioptanTafluprost/Pf17$5,162
Cyclosporine18$4,509
TobradexTobramycin/Dexamethasone15$3,917
Timolol Maleate99$2,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$236$236,048325 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$19$48,68076 claims
AlconSimbrinza$90$9,95935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →